Berodual F UDV Use In Pregnancy & Lactation

Pregnancy: Non-clinical data, combined with available experience in humans have shown no evidence of adverse effects in pregnancy of fenoterol or ipratropium.
Nonetheless, the usual precautions regarding the use of drugs during pregnancy, especially during the first trimester, should be exercised.
The inhibitory effect of fenoterol on uterine contraction should be taken into account.
Lactation: Non-clinical studies have shown that fenoterol hydrobromide, is excreted into breast milk. It is unknown whether ipratropium is excreted into breast milk. But it is unlikely that ipratropium would reach the infant to an important extent, especially when taken by aerosol. However, caution should be exercised when fenoterol hydrobromide/ipratropium bromide (Berodual F UDV) is administered to a nursing woman.
Fertility: Clinical data on fertility are neither available for the combination of ipratropium bromide and fenoterol hydrobromide nor for each of the two components of the combination.
Non-clinical studies performed with the individual components ipratropium bromide and fenoterol hydrobromide showed no adverse effect on fertility (see Pharmacology: Toxicology under Actions).